HEALY JAMES 4

What Happened James Healy, a director of Rapport Therapeutics, was granted a derivative equity award covering 15,200 shares on June 10, 2026. The grant shows a $0.00 acquisition price (no cash paid at grant) and is reported as an award/other acquisition; it is not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-10; grant reported on the same date (filed 2026-06-10).
• Instrument: Derivative equity award (option-style grant) for 15,200 shares; acquisition price reported as $0.00.
• Shares owned after transaction: Not disclosed in the provided filing.
• Vesting note (footnote): The shares underlying this option vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders, subject to Healy’s continued service on the vesting date.
• Filing timeliness: Report appears timely (no late filing indicated).

Context This is a grant of a derivative award (an option-style equity award) rather than an exercised option, immediate sale, or cash purchase. Such awards are commonly used for director compensation and vest over time or upon certain events; they do not necessarily indicate an immediate change in the insider’s economic exposure until vesting/exercise.